Is PGT-M for Monogenic Disease Screening in Georgia Reliable? In-depth Analysis by a Reproductive Doctor

Real Consultation Scenario: An Expectant Mother Carrying the Spinal Muscular Atrophy Gene

"Doctor, I had carrier screening done in my home country and found out I am a carrier for SMA (Spinal Muscular Atrophy). My husband was tested and is not a carrier. But we are still very worried. We saw that PGT-M is available in Georgia and that it can screen for this disease. I want to ask — is PGT-M in Georgia really reliable? Is there a risk of false negatives? If the screening shows an embryo is healthy, does that guarantee the child will not develop the disease after transfer?"

This was a question from a 32-year-old woman who consulted online last week. She had already completed a basic fertility assessment in her home country: AMH 2.8 ng/ml, normal ovarian reserve, and no history of recurrent miscarriage. Her hesitation stemmed from two main concerns: Georgia is not a mainstream destination for IVF, so are the local laboratory standards reliable? And does the PGT-M technology itself carry a risk of missed detection? Let's break this down step by step.

Common Pitfall: Equating "Available" with "Standardized"

Many people assume that because "PGT-M is available in Georgia," every fertility center has the same technical capabilities. In reality, the differences are significant. Key steps in PGT-M include: family linkage analysis or direct mutation detection probe design, embryo biopsy, whole genome amplification, gene sequencing, and result interpretation. Some clinics in Georgia simply send biopsied embryo samples to third-party laboratories (e.g., in Russia, Turkey, or other European countries), while others have their own independent genetics labs on site. The disadvantage of the former is increased logistics time (samples require cold chain transport after biopsy), whereas the latter can deliver results within three days. Reliability depends not just on the country, but critically on whether the center's chosen laboratory holds CAP/CLIA certification or an equivalent quality control system.

Easily Overlooked Detail: Completeness of Proband/Family Specimens

A prerequisite for PGT-M is identifying the specific pathogenic gene mutation. Many families think that if the woman is a carrier, they can proceed directly. However, without a proband (an affected family member) or a complete family linkage analysis, the accuracy of embryo genetic testing drops significantly. Some centers in Georgia accept genetic reports from other hospitals but require peripheral blood samples from the parents and necessary relatives to construct haplotypes. If these preparations are insufficient, it can lead to the frustrating situation of being "unable to determine whether the embryo carries the pathogenic gene." This is a problem many people discover only after arriving in Georgia for PGT-M — their reports are incomplete, requiring new blood draws and delaying the cycle by one to two months.

Cost Factors: Total Expense Depends on Testing Method and Number of Embryos

Note: If the number of embryos is very low (e.g., only 1-2 blastocysts available for biopsy), the cost per embryo after testing is higher. Some clinics offer a "PGT-M package price," but you need to confirm whether it includes the probe design fee — some clinics charge this separately and do not refund it if unsuccessful.

Doctor's Perspective: Technology is Reliable, but Output Quality Depends on the Chain

From a technical standpoint, PGT-M amplifies DNA fragments from embryo cells to directly detect known pathogenic sites. For autosomal dominant diseases (e.g., Huntington's disease), accuracy can reach over 99%; for autosomal recessive diseases (e.g., SMA, beta-thalassemia), accuracy exceeds 97%. Top-tier fertility centers in Georgia use European-standard laboratory equipment (e.g., Illumina sequencers, laser microdissection systems) and employ embryologists trained in Russia or the EU. As long as the laboratory passes external quality controls (e.g., recognition by the European Society of Human Reproduction and Embryology, EHSRE), results are essentially no different from those in European or American labs. However, the issue lies in local regulatory oversight, which is less stringent than in the EU or US. Some clinics may "reduce the number of biopsied cells to save costs" (from the standard 5-7 trophectoderm cells down to 3-4), increasing the risk of allele dropout (ADO), leading to false negatives or inconclusive results. As a reproductive doctor, I advise patients to request the clinic's laboratory certification documents (e.g., ISO 15189 or CAP accreditation) and explicitly ask about the number of cells biopsied.

Country Comparison: Georgia vs. Russia vs. USA vs. Thailand

• Russia: Mature PGT-M technology; most centers have their own genetics labs. Probe design takes 7-10 days, costing approximately $2,500-$3,500. Requires a medical visa and involves higher language barriers.
• USA: Most advanced technology with strictest quality control (mandatory CAP/CLIA). Total cost is around $30,000-$50,000, requiring multiple trips, making it uneconomical for most families.
• Thailand: Some top centers (e.g., Jetanin, BNH) offer PGT-M, but results depend on external labs. Costs are moderate (total ~$15,000-$25,000), but probe design is often outsourced to US companies.
• Georgia: Clear cost advantage (full cycle + PGT-M ~$10,000-$18,000), but laboratory quality is polarized. Good centers have deep collaborations with Russian or European labs; poor centers act merely as "sample collection" services.

Actual Process: Eight-Step Timeline from Consultation to Transfer

1. Genetic Counseling & Family Verification (1-3 months): Requires blood samples (5ml EDTA anticoagulated) from parents, proband, or affected relatives, sent to a partner lab in Georgia for haplotype analysis. If the proband has passed away without stored samples, accuracy drops to ~95% using indirect inference from parental genes.
2. Probe Design & Validation (2-4 weeks): The lab designs specific primers and probes for the mutation and validates sensitivity using positive controls.
3. Ovarian Stimulation & Egg Retrieval (2-3 weeks): Georgian clinics typically use short or antagonist protocols, starting on day 2-3 of menstruation, followed by IVF after retrieval.
4. Blastocyst Culture & Biopsy (5-6 days): Embryos are cultured to the blastocyst stage on day 5 or 6, and 5-7 trophectoderm cells are biopsied for testing.
5. Genetic Testing (3-7 days): Local labs are faster (3 days); external labs take 5-7 days.
6. Chromosomal Aneuploidy Screening (Optional): Some centers combine PGT-M with PGT-A for an additional $800-$1,500, simultaneously screening for numerical abnormalities in chromosomes 21, 18, and 13.
7. Frozen Embryo Transfer (Cycle Adjustment): After results, select embryos without the pathogenic gene and with normal chromosomes for frozen-thawed transfer.
8. Post-Transfer Follow-up (12-14 days): Blood test for pregnancy. If successful, amniocentesis is recommended in the second trimester for confirmation.

Suitable Candidates: Who Should Prioritize PGT-M in Georgia?

• Individuals confirmed as carriers of a monogenic genetic disorder (with identified pathogenic mutation via genetic testing).
• Families with a clear history of genetic disease (e.g., hemophilia, hereditary retinopathy, Charcot-Marie-Tooth disease) and available proband samples.
• Those with a limited budget (total cost under $20,000) willing to accept some laboratory risk.
• Patients who can tolerate a longer preparation period (family verification takes 1-3 months) and have normal ovarian reserve (AMH ≥1.2 ng/ml, antral follicle count ≥8) to ensure at least 3-5 blastocysts for biopsy.

Doctor's Advice: 5 Things to Confirm Before Going to Georgia for PGT-M

1. Does the clinic have its own independent genetics lab? Request the lab's name, address, and certification documents. If outsourced, verify the third-party lab's quality control records (inter-laboratory comparison results from the past year).
2. Are blood samples from both parents required before probe design? If only one parent provides a sample, it may be impossible to distinguish between normal and carrier embryos, significantly reducing the number of usable embryos.
3. How many days after biopsy are results available? Labs taking more than 5 days likely send samples externally or have low internal efficiency, increasing the risk of freeze-thaw damage to embryos.
4. Does the service include embryo chromosomal aneuploidy screening? Skipping aneuploidy screening could lead to transferring an embryo that is "genetically normal but chromosomally abnormal," resulting in miscarriage or birth defects after implantation.
5. Is amniocentesis required after transfer? All PGT-M carries a <1% risk of false negatives. Reputable clinics will explicitly state in writing that "embryo genetic testing cannot replace prenatal diagnosis." Ensure this is clearly stated in the informed consent form.

In summary, PGT-M in Georgia offers competitive advantages in technology and cost, but its "reliability" is highly dependent on the specific clinic and the quality control of its partner laboratory. If you can adequately prepare family samples, choose a center with an independent, certified lab, and accept the need for follow-up prenatal diagnosis, Georgia can be a reasonable option balancing effectiveness and expense. Conversely, if you lack proband samples or require extremely strict accuracy (e.g., >99.9%), it is advisable to prioritize top-tier centers in the US or Russia.

Risk Reminder: PGT-M cannot screen for de novo mutations or polygenic disorders (e.g., type 2 diabetes, schizophrenia). Even if an embryo's genetic results are normal, the child may still be born with other untested genetic conditions. Please maintain realistic expectations.